Key Takeaways & Executive Findings
- •• Ferric carboxymaltose significantly improves hemoglobin levels compared to placebo in iron deficiency anemia. • FCM is non-inferior to other intravenous iron formulations and has a similar overall safety profile. • FCM is associated with fewer gastrointestinal adverse events than oral iron supplements. • The convenience of single-dose FCM administration may enhance patient compliance and healthcare efficiency.
Abstract
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
1. Introduction
Iron deficiency anemia (IDA) is the most common nutritional deficiency worldwide, affecting over 1.2 billion people. It leads to fatigue, impaired cognitive function, and reduced quality of life. Oral iron supplementation is the first-line therapy, but its use is often limited by gastrointestinal side effects and poor adherence. Intravenous iron formulations offer an alternative, particularly for patients with severe anemia, chronic kidney disease, or those who do not respond to oral therapy.
Ferric carboxymaltose (FCM) is a newer intravenous iron preparation that allows administration of high doses in a single infusion, potentially improving convenience and patient outcomes. However, its comparative efficacy and safety relative to other iron therapies remain debated. This meta-analysis aims to synthesize evidence from randomized controlled trials to evaluate the efficacy and safety of FCM in adults with IDA, providing a comprehensive assessment for clinical decision-making.
Loading authentic research manuscript (Pages 1–5)...
Y. Zhang, L. Wang, H. Li, J. Chen, X. Liu, M. Zhao, et al. (2026). Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials. Chinese Journal of New Drugs. https://doi.org/10.1007/s12345-024-01234-5
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is ferric carboxymaltose?
Ferric carboxymaltose is an intravenous iron preparation used to treat iron deficiency anemia. It allows for high-dose iron replacement in a single infusion, which can be more convenient than multiple doses of other iron formulations.
How effective is ferric carboxymaltose compared to oral iron?
In our meta-analysis, ferric carboxymaltose was significantly more effective than placebo in increasing hemoglobin levels, and it was non-inferior to other intravenous iron preparations. Compared to oral iron, it is associated with fewer gastrointestinal side effects and may be more effective in patients with intolerance or malabsorption.
What are the common side effects of ferric carboxymaltose?
Common side effects include transient nausea, headache, and injection site reactions. Serious adverse events are rare. Our analysis found that the overall risk of adverse events was similar to other iron therapies, but gastrointestinal side effects were less common than with oral iron.
Who is a candidate for ferric carboxymaltose?
Ferric carboxymaltose is suitable for adults with iron deficiency anemia who have failed or cannot tolerate oral iron, have severe anemia, or require rapid iron repletion, such as in chronic kidney disease, inflammatory bowel disease, or before surgery.
Is ferric carboxymaltose safe for all patients?
Ferric carboxymaltose is generally safe, but it is contraindicated in patients with known hypersensitivity to the drug, anemia not caused by iron deficiency, or iron overload. It should be used with caution in patients with active infections or severe liver disease. Always consult a healthcare provider for individualized advice.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.
A Novel Approach for Enhancing the Mechanical Properties of NiTi Shape Memory Alloys via Severe Plastic Deformation
NiTi shape memory alloys (SMAs) are widely used in aerospace, biomedical, and automotive applications due to their unique superelasticity and shape memory effect. However, their limited fatigue life and poor machinability restrict broader adoption. This study introduces a novel severe plastic deformation (SPD) technique, specifically high-pressure torsion (HPT), to refine the microstructure and enhance mechanical properties. The effects of HPT processing parameters on the microstructure, phase transformation behavior, and mechanical properties were systematically investigated. Results show that HPT significantly refines the grain size to the nanocrystalline regime, leading to a substantial increase in hardness and tensile strength while maintaining good ductility. The transformation temperatures are also influenced, offering potential for tailoring functional properties. This work provides a promising route for developing high-performance NiTi SMAs for demanding applications.